Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 200 av 272 resultater
Tid
Selskap
Tittel
Sektor
Kategori
15 Mar 2023
22:02 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
14 Mar 2023
22:00 CET
CELLECTIS
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
20103010 Biotechnology
-
14 Mar 2023
22:00 CET
CELLECTIS
Cellectis présentera un poster sur les cellules CAR T MUC1 éditées par TALEN® ciblant le cancer du sein triple négatif à la réunion annuelle de l'American Association of Cancer Research (AACR)
20103010 Biotechnology
-
08 Mar 2023
22:45 CET
CELLECTIS
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
20103010 Biotechnology
-
08 Mar 2023
22:45 CET
CELLECTIS
Cellectis publie ses résultats financiers du quatrième trimestre 2022 et de l’exercice 2022
20103010 Biotechnology
-
06 Mar 2023
22:30 CET
CELLECTIS
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
20103010 Biotechnology
-
06 Mar 2023
22:30 CET
CELLECTIS
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
20103010 Biotechnology
-
01 Mar 2023
22:30 CET
CELLECTIS
Cellectis présentera ses résultats financiers du quatrième trimestre et de l’année 2022 le 8 mars 2023
20103010 Biotechnology
-
01 Mar 2023
22:30 CET
CELLECTIS
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
20103010 Biotechnology
-
09 Feb 2023
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
09 Feb 2023
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
08 Feb 2023
01:01 CET
CELLECTIS
Cellectis annonce le règlement livraison de son offre d’ADS et l’exercice de l’option de surallocation des banques garantes
20103010 Biotechnology
-
08 Feb 2023
01:01 CET
CELLECTIS
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
20103010 Biotechnology
-
03 Feb 2023
15:34 CET
CELLECTIS
Cellectis complète l’annonce des modalités définitives de son offre d’ADS avec la répartition de son capital après la réalisation de son offre d’ADS
20103010 Biotechnology
-
03 Feb 2023
15:33 CET
CELLECTIS
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
20103010 Biotechnology
-
03 Feb 2023
06:49 CET
CELLECTIS
Cellectis annonce les modalités définitives de son offre d’ADS
20103010 Biotechnology
-
03 Feb 2023
06:48 CET
CELLECTIS
Cellectis Announces Pricing of Follow-On Offering
20103010 Biotechnology
-
02 Feb 2023
22:01 CET
CELLECTIS
Cellectis Announces Launch of Follow-On Offering
20103010 Biotechnology
-
02 Feb 2023
22:01 CET
CELLECTIS
Cellectis annonce le lancement d’une nouvelle offre d’ADS
20103010 Biotechnology
-
20 Jan 2023
22:30 CET
CELLECTIS
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
20103010 Biotechnology
-
20 Jan 2023
22:30 CET
CELLECTIS
Cellectis modifie sa note convertible de 20 millions de dollars dans le cadre de l’accord de collaboration avec son partenaire Cytovia Therapeutics
20103010 Biotechnology
-
17 Jan 2023
13:10 CET
CELLECTIS
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
20103010 Biotechnology
-
17 Jan 2023
13:10 CET
CELLECTIS
Calyxt et Cibus annoncent la signature d’un Accord de Fusion
20103010 Biotechnology
-
09 Jan 2023
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
09 Jan 2023
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
04 Jan 2023
23:09 CET
CELLECTIS
Cellectis met en place un programme At the Market sur le Nasdaq
20103010 Biotechnology
-
04 Jan 2023
23:08 CET
CELLECTIS
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
20103010 Biotechnology
-
29 Dec 2022
22:30 CET
CELLECTIS
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
20103010 Biotechnology
-
29 Dec 2022
22:30 CET
CELLECTIS
Mayflower Bioventures lance sa première spin-off, Primera Therapeutics, en collaboration avec Cellectis pour développer une plateforme d'édition du génome pour traiter les maladies mitochondriales
20103010 Biotechnology
-
28 Dec 2022
22:30 CET
CELLECTIS
Cellectis obtient un crédit d’un montant de 40 millions d’euros de la Banque Européenne d’Investissement pour accompagner ses activités de recherche, de développement et d’innovation
20103010 Biotechnology
-
28 Dec 2022
22:30 CET
CELLECTIS
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
20103010 Biotechnology
-
22 Dec 2022
22:30 CET
CELLECTIS
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
20103010 Biotechnology
-
22 Dec 2022
22:30 CET
CELLECTIS
Cellectis annonce que son produit candidat UCART22, fabriqué en interne, a été administré à un premier patient pour le traitement de la leucémie lymphoblastique aigüe
20103010 Biotechnology
-
16 Dec 2022
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
16 Dec 2022
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
13 Dec 2022
13:30 CET
CELLECTIS
Cellectis annonce des données cliniques préliminaires positives pour UCART22 dans la LLA et UCART123 dans la LAM
20103010 Biotechnology
-
13 Dec 2022
13:30 CET
CELLECTIS
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
20103010 Biotechnology
-
01 Dec 2022
22:41 CET
CELLECTIS
Cellectis organise un webcast en direct le 13 décembre 2022
20103010 Biotechnology
-
01 Dec 2022
22:40 CET
CELLECTIS
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
20103010 Biotechnology
-
10 Nov 2022
15:05 CET
CELLECTIS
Cellectis présente des données précliniques sur des cellules « smart » CAR T éditées par TALEN® pouvant surmonter les principaux défis du ciblage des tumeurs solides à la réunion annuelle de la Society for Immunotherapy of Cancer (SITC)
20103010 Biotechnology
-
10 Nov 2022
15:05 CET
CELLECTIS
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
20103010 Biotechnology
-
10 Nov 2022
08:48 CET
CELLECTIS
Cellectis publie un article dans Frontiers Bioengineering and Biotechnology sur une stratégie de multiplexage d’ingénierie du génome efficace en combinant la technologie TALEN® et les base editor TALE (TALE-BE)
20103010 Biotechnology
-
10 Nov 2022
08:48 CET
CELLECTIS
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
20103010 Biotechnology
-
08 Nov 2022
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
08 Nov 2022
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
03 Nov 2022
21:44 CET
CELLECTIS
Cellectis publie ses résultats financiers pour le troisième trimestre et pour les neuf premiers mois de l’année 2022
20103010 Biotechnology
-
03 Nov 2022
21:36 CET
CELLECTIS
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
20103010 Biotechnology
-
03 Nov 2022
21:05 CET
CELLECTIS
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
20103010 Biotechnology
-
03 Nov 2022
21:05 CET
CELLECTIS
Cellectis présentera des données cliniques sur AMELI-01 et des données précliniques sur UCARTCS1 à l’American Society of Hematology 2022
20103010 Biotechnology
-
27 Oct 2022
22:37 CEST
CELLECTIS
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du troisième trimestre 2022 le vendredi 4 novembre à 14h00 CET
20103010 Biotechnology
-
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva